SDIC Leads $39M Round In Chinese Small Interfering RNA Drug Developer Ribo

An advanced manufacture industrial investment fund under China’s SDIC Fund Management Co. has led a RMB270 million (US$39 million) series B round in Suzhou Ribo Life Science Co. Ltd, a small interfering RNA (siRNA) drug developer.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets